Menu
Ketorolac

Ketorolac Tromethamine

Ketorolac or ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) in the family of heterocyclic acetic acid derivatives, used as an analgesic. Ketorolac was developed in 1989 by Syntex Corp. (now Roche Bioscience, which is a wholly owned subsidiary of Roche holding Ltd., the parent company of Roche).[1] It was approved by FDA on 30 November 1989 and introduced as Toradol by Syntex.[2] The ophthalmic (i.e., eye-drop) form was approved by FDA on 9 November 1992 and was introduced as Acular eye drops by Allergan under license from Syntex.[3] An intranasal formulation of ketorolac tromethamine was approved by FDA on 14 May 2010 and introduced as Sprix Nasal Spray by Daiichi Sankyo[4] for short-term management of moderate to moderately severe pain requiring analgesia at the opioid level.

 Make an enquiry for this product

Starting at

Compare

Product Description


(±)-5-benzoyl-2,3-dihydro-
1H-pyrrolizine-1-carboxylic acid,
2-amino-2-(hydroxymethyl)-1,3-propanediol

Trade names Toradol, Acular and Sprix
AHFS/Drugs.com monograph
MedlinePlus a693001
Licence data US Daily Med:link
Pregnancy
category
AU: C
US: C (Risk not ruled out)
Legal status AU: S4 (Prescription only)
US: ℞-only
Routes of
administration
Oral, I.M., I.V.

Bioavailability 100% (All routes)
Metabolism Hepatic
Biological half-life 3.5–9.2 hrs, young adults;
4.7–8.6 hrs, elderly (mean age 72)
Excretion Renal: 91.4% (mean)
Biliary: 6.1% (mean)

CAS Number 74103-06-3
ATC code M01AB15 S01BC05
PubChem CID: 3826
DrugBank DB00465
ChemSpider 3694
UNII YZI5105V0L
KEGG D08104
ChEBI CHEBI:6129
ChEMBL CHEMBL469
PDB ligand ID KTR (PDBe, RCSB PDB)

Formula C15H13NO3
Molecular mass 255.27 g/mol
SMILES[show]
InChI[show]